Conmed (CNMD) Cost of Revenue (2010 - 2026)

Conmed (CNMD) has reported Cost of Revenue for 17 consecutive years, with $146.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue fell 5.19% year-over-year to $146.0 million; the trailing twelve-month figure through Jun 2026 stood at $606.3 million (up 4.03% YoY), and the FY2025 full-year result was $624.2 million, up 8.76% from the prior year.
• Cost of Revenue grew to $146.0 million in Q2 2026 per CNMD's latest filing, from $133.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $171.8 million in Q3 2025 and bottomed at $106.3 million in Q1 2022.
• Historically, Cost of Revenue has averaged $140.0 million across 5 years, with a median of $141.9 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Cost of Revenue soared 31.8% in 2023, then dropped 6.9% in 2026.
• Over 5 years, Cost of Revenue stood at $119.0 million in 2022, then gained by 21.73% to $144.9 million in 2023, then advanced by 1.88% to $147.6 million in 2024, then climbed by 4.95% to $154.9 million in 2025, then retreated by 5.73% to $146.0 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $146.0 million, $133.6 million, and $154.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.